Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: Intermediate experience in pediatric heart transplantation recipients

Matthews KL, Gossett J, Vande Kappelle P, Jellen G, Pahl E. Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: Intermediate experience in pediatric heart transplantation recipients.
Pediatr Transplantation 2010: 14:402–408. © 2010 John Wiley & Sons A/S.

[1]  B. McCrindle,et al.  The profile of renal function over time in a cohort of pediatric heart transplant recipients , 2009, Pediatric transplantation.

[2]  H. Ross,et al.  497: Incidence and Underlying Cause of Anemia in Cardiac Transplant Recipients Treated with Sirolimus , 2009 .

[3]  D. Kaye,et al.  Outcomes Following De Novo CNI‐Free Immunosuppression After Heart Transplantation: A Single‐Center Experience , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  N. Lloberas,et al.  Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  K. Shu,et al.  Possible mechanism by which rapamycin increases cyclosporine nephrotoxicity. , 2008, Transplantation proceedings.

[6]  A. Yeung,et al.  Effect of rapamycin therapy on coronary artery physiology early after cardiac transplantation. , 2008, American heart journal.

[7]  D. Dunkler,et al.  Development of Proteinuria After Switch to Sirolimus‐Based Immunosuppression in Long‐Term Cardiac Transplant Patients , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  W. Kremers,et al.  Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation , 2007, Circulation.

[9]  J. Herreros,et al.  Impact on renal function of the use of sirolimus in cardiac transplantation. , 2007, Transplantation proceedings.

[10]  E. Pahl.  Statins in the prevention of transplant coronary artery disease: In pediatric heart recipients , 2007, Pediatric transplantation.

[11]  A. Knez,et al.  Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  M. Edwardes,et al.  Calcineurin inhibitor substitution with sirolimus vs. reduced‐dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients , 2007, Clinical transplantation.

[13]  A. Ojo,et al.  Pre-transplant risk factors for chronic renal dysfunction after pediatric heart transplantation: a 10-year national cohort study. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  M. Zembala,et al.  Surgical wound‐healing complications in heart transplant recipients treated with rapamycin , 2007, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[15]  P. Escribano,et al.  Sirolimus-associated interstitial pneumonitis in 3 heart transplant recipients. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  S. Hunt,et al.  Wound Healing Complications with De Novo Sirolimus Versus Mycophenolate Mofetil‐Based Regimen in Cardiac Transplant Recipients , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  C. Belsha,et al.  Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  M. Mamzer-Bruneel,et al.  Brief Communication: Sirolimus-Associated Pneumonitis: 24 Cases in Renal Transplant Recipients , 2006, Annals of Internal Medicine.

[19]  E. Burdmann,et al.  Switch from Calcineurin Inhibitors to Sirolimus-Induced Renal Recovery in Heart Transplant Recipients in the Midterm Follow-up , 2006, Transplantation.

[20]  N. Banner,et al.  Reversible sirolimus-associated pneumonitis after heart transplantation. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[21]  R. Rodeheffer,et al.  Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[22]  M. Mack,et al.  Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  A. Dipchand,et al.  Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[24]  C. Mavroudis,et al.  Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[25]  D. Baran,et al.  Calcineurin Inhibitor-Associated Early Renal Insufficiency in Cardiac Transplant Recipients , 2004, American Journal of Cardiovascular Drugs.

[26]  G. Filler,et al.  Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? , 2003, Pediatric Nephrology.

[27]  D. Burkhoff,et al.  Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy , 2003, Circulation.

[28]  R. Langer,et al.  Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients1. , 2002, Transplantation.

[29]  G. Mazariegos,et al.  Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. , 2001, Transplantation.

[30]  M. Oz,et al.  Long-term outcomes after cardiac transplantation: an experience based on different eras of immunosuppressive therapy. , 2001, The Annals of thoracic surgery.

[31]  S. Sehgal.  Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. , 1998, Clinical biochemistry.

[32]  R. Browne,et al.  Limitations to body length/serum creatinine ratio as an estimate of glomerular filtration in children , 1996, Pediatric Nephrology.

[33]  L. Brion,et al.  The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. , 1987, Pediatric clinics of North America.